CN Patent

CN112292117B — 包含依鲁替尼的配制品/组合物

Assigned to Janssen Pharmaceutica NV · Expires 2024-06-07 · 2y expired

What this patent protects

披露了包含依鲁替尼：(I)的配制品/组合物，连同用于制备此类配制品/组合物的方法，以及包括此类配制品/组合物的使用的疾病或病症的治疗方法。

USPTO Abstract

披露了包含依鲁替尼：(I)的配制品/组合物，连同用于制备此类配制品/组合物的方法，以及包括此类配制品/组合物的使用的疾病或病症的治疗方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112292117B
Jurisdiction
CN
Classification
—
Expires
2024-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.